SOLICITATION NOTICE
A -- Preclinical In Vitro and In Vivo Screening Assays
- Notice Date
- 6/18/2002
- Notice Type
- Solicitation Notice
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
- ZIP Code
- 20852
- Solicitation Number
- N01-CN-25026-76
- Response Due
- 11/13/2002
- Point of Contact
- Cynthia Washington, Contract Specialist, Phone (301) 435-3798, Fax (301) 402-8579, - Cynthia Washington, Contract Specialist, Phone (301) 435-3798, Fax (301) 402-8579,
- E-Mail Address
-
cw212f@nih.gov, cw212f@nih.gov
- Description
- Requests for Proposals (RFP) N01-CN-25026-76, entitled: Preclinical In Vivo and In Vitro Screening Assays. The Division of Cancer Prevention (DCP), of the National Cancer Institute (NCI) is seeking proposals from qualified organizations who have the ability to screen potential cancer preventive agents in a variety of mechanism-based in vitro and in vivo assays and establish the infrastructures composed of one or more collaborating institutions that will conduct these mechanism-based screening assays. The assays will assess the potential of various agents to inhibit, reverse, or delay early carcinogenesis by evaluating the effects of these agents on a variety of endpoints, including but not limited to, specific molecular targets, transformation, proliferation, and apoptosis; and validation of new assays and techniques, such as quantitative image analysis. For the in vivo tests a required endpoint shall be the histopathologic evaluation of cancers. The agents to be studied shall include agents developed by the pharmaceutical and other industries and provided to the NCI for collaborative development as well as commercially available agents, agents developed by the NCI, and agents nominated by academic investigators through the RAPID program (http://www.cancer.gov/prevention/rapid/). The specific goals are to (1) screen and identify potential cancer preventive agents in various mechanism-based in vitro assays relating to molecular targets and the inhibition, reversal, or delay of early carcinogenesis and (2) evaluate further potential cancer preventive agents, that have preliminary supportive data from mechanism-based in vitro assays, in various standardized and newly developed in vivo rodent model systems of experimental carcinogenesis. Contracts awarded as a result of this solicitation will replace the current In Vitro Master Agreement pool and the current In Vivo Master Agreement pool. Contracts will be awarded to the offerors who demonstrate the ability to conduct mechanism-based in vitro and in vivo bioassays of potential cancer preventive agents. Offerors for these contracts must demonstrate that they have knowledge of drug development, preferably in disease prevention, and expertise in cell free, cell culture, and molecular assay techniques and in laboratory animal bioassay methods. Offerors need to provide evidence of their own expertise and access to expertise in such areas as molecular biology, pathology, imaging, statistical analyses, analytical chemistry, and other potentially relevant laboratory methodologies. Contracts awarded as a result of this solicitation will be cost-reimbursement completion type, with managed work assignments. Work Assignments will be initiated by the Project Officer, who will forward a request to the Principal Investigator stating the period of performance, specific work to be performed, and the deliverables. Within the specified period, the Contract will submit to the Project Officer a detailed description of the technical approach to be used in carrying out the Work Assignment, and an estimate of the required effort and cost. The cost of a Work Assignment shall not exceed the funds currently allotted to the contract. With the concurrence of the Project Officer, the Contracting Officer will then execute the Work Assignment. Offerors will have flexibility to subcontract with additional sites to provide specific technical expertise that is needed for the individual Work Assignments. The duration of each study will depend on the in vitro assay or the laboratory animal model and will be specified in each Work Assignment. The contractor selected shall be responsible for providing the chemopreventive agent except in instances when the NCI wants an agent tested that may not be available to the contractor. In such cases, the Government shall bear the expense of providing an agent. The specific work assignment shall specify whether the contractor shall be expected to provide the agent. It is anticipated that six (6) awards will be made and that these contracts will be incrementally-funded with a period of performance of five (5) years. Offerors must submit a proposal that addresses both task areas, that is, In Vitro and In Vivo Screening Assays. Only proposals from offerors who demonstrate the capability to perform both In Vitro and In Vivo Screening Assays will be considered for award. The North American Industry Classification System (NAICS) code is 541710. The RFP will be issued ELECTRONICALLY July 3, 2002. The RFP will be available on the Research Contracts Branch (RCB) web site at: http://rcb.nci.nih.gov Click on "Current Request for Proposals." It is the offeror's responsibility to monitor the above internet site for the release of this solicitation and amendments, if any. POTENTIAL OFFERORS WILL BE RESPONSIBLE FOR DOWNLOADING THEIR OWN COPY OF THE SOLICITATION AND AMENDMENTS. Point of Contact: Cynthia D. Washington, Contract Specialist, Prevention, Control and Population Sciences Section (PCPSS), Research Contracts Branch (RCB), NCI, 6120 Executive Boulevard, Room 6002, MSC 7195, Bethesda, Maryland 20892-7195. Phone: (301) 435-3798; fax: (301) 402-8579. ALL QUESTIONS/INQUIRIES SHALL BE SUBMITTED ELECTRONICALLY TO CYNTHIA D. WASHINGTON, CONTRACT SPECIALIST, at cw212f@nih.gov. All requests for information should reference RFP No. N01-CN-25026-76. No collect calls will be accepted. Based upon market research, the Government is not using the policies contained in Part 12, Acquisition of Commercial Items, in its solicitation for the described supplies or services. However, interested persons may identify to the Contract Specialist their interest and capability to satisfy the Government's requirement with a commercial item within 15 days of this notice.
- Record
- SN00095201-W 20020620/020618213637 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |